Back to Search Start Over

Soft Tissue Sarcoma, Version 2.2022

Authors :
von Mehren, Margaret
Kane, John M.
Agulnik, Mark
Bui, Marilyn M.
Carr-Ascher, Janai
Choy, Edwin
Connelly, Mary
Dry, Sarah
Ganjoo, Kristen N.
Gonzalez, Ricardo J.
Holder, Ashley
Homsi, Jade
Keedy, Vicki
Kelly, Ciara M.
Kim, Edward
Liebner, David
McCarter, Martin
McGarry, Sean V.
Mesko, Nathan W.
Meyer, Christian
Pappo, Alberto S.
Parkes, Amanda M.
Petersen, Ivy A.
Pollack, Seth M.
Poppe, Matthew
Riedel, Richard F.
Schuetze, Scott
Shabason, Jacob
Sicklick, Jason K.
Spraker, Matthew B.
Zimel, Melissa
Hang, Lisa E.
Sundar, Hema
Bergman, Mary Anne
Source :
J Natl Compr Canc Netw
Publication Year :
2022

Abstract

Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues. The evaluation and treatment of patients with STS requires a multidisciplinary team with demonstrated expertise in the management of these tumors. The complete NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Soft Tissue Sarcoma provide recommendations for the diagnosis, evaluation, and treatment of extremity/superficial trunk/head and neck STS, as well as retroperitoneal/intra-abdominal STS, desmoid tumors, and rhabdomyosarcoma. This portion of the NCCN Guidelines discusses general principles for the diagnosis and treatment of retroperitoneal/intra-abdominal STS, outlines treatment recommendations, and reviews the evidence to support the guidelines recommendations.

Details

Language :
English
Database :
OpenAIRE
Journal :
J Natl Compr Canc Netw
Accession number :
edsair.pmid..........fc0b07ec01363665d237eca038b0ae78